InterVenn Biosciences raises $34 million to accelerate cancer test development with AI
November 26, 2020
InterVenn Biosciences today raised $34 million to further develop its platform for precision medicine. The New York-based startup says the funds will be used to accelerate its go-to-market, expansion, and ongoing product R&D efforts.
Mass spectrometry, a technique that measures the mass-to-charge ratio of ions, can be applied to genomics studies with implications for clinical medicine. But…